Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status

Biochemical Pharmacology

Volumn 74, Issue 1, 2007, Pages 20-27

  Martelli, Laura ^a   Di Mario, Francesco ^b   Botti, Paolo ^b   Ragazzi, Eugenio ^a   Martelli, Mario ^a   Kelland, Lloyd ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell sensitivity; Drug accumulation; Drug resistance; Hydrophobicity; p53; Pt drugs; Pt DNA binding; U2 OS human osteosarcoma cell line

Indexed keywords

CISPLATIN; OXALIPLATIN; PROTEIN P53; SATRAPLATIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; HUMAN; HUMAN CELL; HYDROPHOBICITY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; WILD TYPE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34249065468     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.025     Document Type: Article

References (34)

1. Kelland L.R. Preclinical perspectives in platinum resistance. Drugs 59 Suppl 4 (2000) 18
2. Siddik Z.H., Mims B., Lozano G., and Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58 (1998) 698-703
3. Trimmer E.E., and Essigmann J.M. Cisplatin. Essays Biochem 34 (1999) 191-211
4. Martelli L., Di Mario F., Ragazzi E., Apostoli P., Leone R., Perego P., et al. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 72 (2006) 693-700
5. Screnci D., McKeage M.J., Galettis P., Hambley T.W., Palmer B.D., and Baguley B.C. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82 (2000) 966-972
6. Lanzi C., Perego P., Supino R., Romanelli S., Pensa T., Carenini N., et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 55 (1998) 1247-1254
7. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
8. Houldsworth J., Xiao H., Murty V.V., Chen W., Ray B., Reuter E., et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16 (1998) 2345-2349
9. Manic S., Gatti L., Carenini N., Fumagalli G., Zunino F., and Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3 (2003) 21-29
10. Gatti L., Supino R., Perego P., Pavesi R., Caserini C., Carenini N., et al. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ 9 (2002) 1352-1359
11. Fokkema E., Groen H.J., Helder M.N., de Vries E.G., and Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63 (2002) 1989-1996
12. Perego P., Righetti S.C., Supino R., Delia D., Caserini C., Carenini N., et al. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 2 (1997) 540-548
13. Perego P., Caserini C., Gatti L., Carenini N., Romanelli S., Supino S., et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 55 (1999) 528-534 [Erratum in: Mol Pharmacol 1999;55:1108]
14. Beretta G.L., Gatti L., Tinelli S., Corna E., Colangelo D., Zunino F., et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 68 (2004) 283-291
15. Bonetti A., Apostoli P., Zaninelli M., Pavanel F., Colombatti M., Cetto G.L., et al. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 2 (1996) 1829-1835
16. Kirby K.S., and Cook E.A. Isolation of deoxyribonucleic acid from mammalian tissues. Biochem J 104 (1967) 254-257
17. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Lab Press, New York p. E.3:E.5
18. Moeller N., Kangarloo B.S., Puscasu I., Mock C., Krebs B., and Wolff J.E.A. Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity. Anticancer Res 20 (2000) 4435-4440
19. Han I., Nguyen T., Yang L., Khokhar A.R., and Perez-Soler R. Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in LoVo and LoVo/PDD cells. Anticancer Drugs 5 (1994) 64-68
20. Samimi G., and Howell S.B. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transportes. Cancer Chemother Pharmacol 57 (2006) 781-788
21. Liang X., and Huang Y. Physical state changes of membrane lipids in human lung adenocarcinoma A549 cells and their resistance to cisplatin. Int J Biochem Cell Biol 34 (2002) 1248-1255
22. Checkhun V.F., Solyanik G.I., Kulik G.I., Tryndiak V.P., Todor I.N., Dovbeshko G.I., et al. The SEIRA spectroscopy data of nucleic acids and phospholipids from sensitive and drug resistant rat tumors. J Exp Clin Cancer Res 21 (2002) 599-607
23. 1H NMR mobile lipid intensity and cholesterol in two human tumor multidrug resistant cell lines (MCF-7 and LoVo). Biochim Biophys Acta 1531 (2001) 111-131
24. 1H NMR spectroscopy and phosphatidylserine externalization. Anticancer Res 21 (2001) 3915-3919
25. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., et al. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res 52 (1992) 3857-3864
26. Loh S.Y., Mistry P., Kelland L.R., Abel G., and Harrap K.R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br J Cancer 66 (1992) 1109-1115
27. Gately D.P., and Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 57 (1993) 1171-1176
28. Cere V., Grossi L., Munari D., Pollicino S., Martelli L., and Martelli M. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs. Anticancer Res 26 (2006) 1815-1819
29. Goodisman J., Hagrman D., Tacka K.A., and Souid A.K. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 57 (2006) 257-267
30. Mishima M., Samimi G., Kondo A., Lin X., and Howell S.B. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38 (2002) 1405-1412
31. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., and Juniewicz P. Sequence and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54 (1998) 770-777
32. Arnould S., Hennebelle I., Canal P., Bugat R., and Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39 (2003) 112-119
33. Reardon J.T., Vaisman A., Chaney S.G., and Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59 (1999) 3968-3971
34. Kalayda G.V., Zhang G., Abraham T., Tanke H.J., and Reedijk J. Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs. J Med Chem 48 (2005) 5191-5202